Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer (TA944)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 January 2024
Endoscopic bipolar radiofrequency ablation for malignant biliary obstruction (IPG794)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 14 November 2024
Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA1005)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 September 2024
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments (TA948)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 January 2024
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency (TA914)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 September 2023
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal) (TA966)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2024
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 August 2021
Photodynamic therapy for bile duct cancer (IPG134)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 27 July 2005
Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma (IPG630)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 31 October 2018
The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system (MIB21)Product type:AdviceProgramme:Medtech innovation briefingPublished: 12 February 2015
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments ID6388Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC